Maitri Health Technologies Signs Definitive Agreement to Acquire Bloom Health Creating a New Generation of Occupational Health Services
Merged operations of Bloom and Maitri will raise the bar in health and safety as a complete digital, clinical, health and safety platform for Fortune 500 companies, movie studios, education and government institutions.
VANCOUVER, BC, July 2, 2021 /CNW/ - Maitri Health Technologies Corp. ("Maitri" or the "Company") (CSE: MTEC) (FRA: D84) announces that it has signed a definitive agreement, dated as of June 29, 2021, to acquire Texas-based Round Hill Health Partners, LLC dba Bloom Health Partners ("Bloom Health"). The deal brings together Maitri's innovative cloud strategy for safe workplaces with Bloom Health's occupational health system serving clientele across the United States. The transaction is expected to close in July 2021.
The combined teams will continue to grow Bloom Health's client base in the United States while expanding its best-in-class clinical operations in other countries. Bloom Health's occupational health and safety solutions currently serve Fortune 500 clients, movie studios, sports and entertainment events. Maitri will be launching a cloud software platform that coordinates health and safety for organizations.
"Helping organizations run safely well into the future will be possible with the combination of our respective teams' expertise and operations," said Andrew Morton, Maitri CEO. "As a health-tech company, our cloud software platform strategy will enable organizations of all types to return to work and intelligently maintain long-term operations. The Bloom acquisition places us as a leading end-to-end occupational health and safety provider."
"We're thrilled to be joining forces with Maitri," said Cole Lysaught, co-founder of Bloom Health. "Bloom's customizable, turnkey health and safety solutions enable organizations in the private and public sectors to provide innovative health services to their workforces and those they serve."
Transaction Details
Total consideration for the transaction is US$20,090,000, which will be satisified through the issuance of securities that are exchangeable into 28,030,000 common shares of Maitri (the "Consideration Shares") and completion of cash payments totaling US$12,250,000 (the "Consideration Payments"). The number of Consideration Shares is based on the volume-weighted average trading price price of the common shares of Maitri in the ten trading days prior to the entering of the definitive agreement. The Consideration Payments will be payable quarterly through December 31, 2023, based upon a rate of US$0.70 for every US$1.00 of earnings before interest, taxes, depreciation and amortization ("EBITDA") generated by Bloom Health.
The members of Bloom Health will also be entitled to receive additional bonus payments based upon the achievement of the following milestones:
a one-time payment of US$10,000,000, payable in cash or common shares of the Company, at the election of the members of Bloom Health, upon Bloom Health achieving EBITDA of at least $27,500,000 by December 31, 2023;
a one-time payment of US$20,000,000, payable in cash or common shares of the Company, at the election of the Company, upon the Company achieving a market capitalization of Cdn$325,000,000 for thirty consecutive trading days prior to December 31, 2023; and
a one-time payment of US$20,000,000, payable in cash or common shares of the Company, at the election of the members of Bloom Health, upon Bloom Health achieving EBITDA of at least US$52,500,000 by December 31, 2023.
The Company is at arms-length from each of Bloom Health and its members. The transaction does not constitute a reverse-takeover or fundamental change for the Company under the applicable policies of the Canadian Securities Exchange, nor is it expected to result in the creation of any new insider or control person of the Company. In connection with completion of the transaction, the Company has granted Bloom Health the right to appoint two nominees to the board of directors of Maitri. No changes to management of the Company are anticipated in connection with completion of the Acquisition.
Completion of the transaction is subject to customary closing conditions.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws. Such securities may not be offered or sold in the United States absent such registration, or an available exemption therefrom.
About Maitri Health Technologies
Maitri Health Technologies Corp. (CSE: MTEC, FRA: D84) is a global platform for healthcare security. Our mission is to enhance safety and quality of life, and keep organizations and economies running. Maitri offers a system for businesses to run safely. Our stable, scalable system is integrated with unique digital technology to deliver a comprehensive healthcare supply and workplace management platform. For more information: https://maitrihealth.ca/
About Bloom Health
Bloom Health is a trusted occupational health and safety service provider, offering a network of top healthcare professionals and integrated laboratories for Fortune 500 companies, Hollywood productions and major sporting and music events. Bloom Health's mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. For more information, visit www.bloomhealthpartners.com.
This news release includes forward-looking statements that are subject to risks and uncertainties, including statements regarding the timing, completion and benefits of the Bloom Health transaction, and future payments in connection therewith. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential inability to satisfy the applicable closing conditions or the risk of delay, the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE Maitri Health Technologies Corp.
Scientists discover why some cancer cells are immune to chemotherapyDiscovery opens up potential for new treatments
Scientists discover why some cancer cells are immune to chemotherapyDiscovery opens up potential for new treatments
30 June 2021 Scientists have discovered why some cancer cells become immune to chemotherapy.New research by scientists at the University of Bradford, the University of Sheffield and Oxford University established a link between cancer cells which are deprived of oxygen - a state known as hypoxia - and the production of an enzyme called senataxin, which aids DNA repair.Professor Sherif El-Khamisy, Director of the Institute of Cancer Therapeutics at the University of Bradford, said an increase in senataxin in the hypoxic cancer cells effectively made them immune to chemotherapy.DNA damageHe said: “Most cancers, solid tumours in particular, become hypoxic - in other words, they suffer from lack of oxygen - especially the core of the tumour. This is because they don’t reach enough blood vessels and therefore have less oxygen, so they become hypoxic and this means they are resistant to chemotherapy.”Chemotherapy works by inducing DNA damage in cancer cells but if cells are able to produce senataxin, they are able to repair that damage and therefore become immune to chemotherapy. A lack of oxygen means they overproduce senataxin.Prof El-Khamisy, from the School of Pharmacy and Medical Sciences, said: “Chemotherapy works by inducing DNA damage in cancerous cells. What we found was that, in those hypoxic cells, there was an increase of an enzyme called senataxin, which modulates DNA repair. This is the first time this link has been established.”New researchScientists made the discovery after growing cancer cells on petri dishes in a low oxygen environment - typically 0.01 per cent oxygen - to mimic the conditions in the core of cancer tumours. The paper desribing their findings was published in Nature Communications on June 17.The next stage of the research will involve further trials and modelling to see whether reducing or inhibiting senataxin makes chemotherapy more effective. The discovery also comes just weeks after scientists at Bradford published new research about naked mole rats and their natural resistance cancer.Commenting on the latest discovery, Prof El-Khamisy added: “We’re excited by this latest development, it’s the first time this link has been made and it opens up the potential for new lines of treatment. Cancer research is often a slow process, with small steps being taken by different teams - our hope is that this discovery will push the research forward, perhaps allowing others to take the next step.” Pictures: 1) Prof Sherif El-Khamisy, Director of the Institute of Cancer Therapeutics at the University of Bradford. Picture credit: University of Bradford.
LifeLabs’ COVID-19 response management in communications wins 2021 Gold Quill Award
Toronto, Ontario, June 30, 2021 (GLOBE NEWSWIRE) -- We’re honoured to announce that the LifeLabs team has been recognized by the International Association of Business Communicators (IABC) with a Gold Quill award for its communications strategy under the new category COVID-19 response and recovery management and communication. The field received 482 entries from 22 countries.
For more than 40 years, the IABC Gold Quill Awards have recognized excellence in business communication and is globally acknowledged as one of the most prestigious awards programs in the industry. The reviewers use the 7-Point Global Scale of Excellence and the rubrics and the integrity of the process for which IABC has come to be known, according to the IABC website. LifeLabs’ entry demonstrated how the projects applied a full range of planning and management skills, including research, analysis, strategy, tactical implementation and evaluation.
Throughout the COVID-19 pandemic, LifeLabs has remained open and operational to provide essential testing and laboratory services for Canadians. To ensure the success of each project and initiative, Communications played a vital role—providing accessible and reliable content that worked to celebrate LifeLabs' role as an integral part of the health care system and key supporter of Canadians during the pandemic.
"The challenge of COVID-19 has brought out the best in us, and it has further strengthened our commitment to our customers and each other,” says Charles Brown, CEO and President of LifeLabs. “The pandemic not only changed the world but the way we work in many ways. We created new ways of working that demanded agility and ingenuity by re-examining old structures, processes and thinking into new mental and business models that have us thriving despite these unprecedented times. These changes cultivated a new level of resilience and purpose for the LifeLabs teams."
“Responding to this pandemic required critical preparedness and the response of a cross-functional team at LifeLabs, and communication was an essential part of that strategy,” says Suset Silva, Director, Corporate Communications & Community Engagement. “At a time of great uncertainty and change, communication is even more critical in how we support the business, our customers and employees. This award is a testament to the team work of the COVID response team, the communications team, and our frontline employees who carried the messages forward with our customers, healthcare providers and stakeholders. Thank you for collaborating and communicating together.
The winning entry noted that with such a large workforce of over 6,000 employees, spread out throughout the nation, effective internal and external communications were critical to ensuring continued, safe care during the pandemic. The communication plan followed suit, utilizing cross-channel methods to share important updates and opportunities across the business. Some of the strategies highlighted in the entry included creating:
a proactive informational campaign to share via social channels (FAQ/Did you know)
a COVID-19 microsite for dedicated updates and information for customers and health care providers
a “health care heroes” communication campaign, recognizing the tremendous work of our frontline employees
extensive communications and public relations plans for each new service and product added during COVID-19 pandemic.
About LifeLabs
LifeLabs is Canada’s leading provider of laboratory diagnostic information and digital health connectivity systems, enabling patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. We support 20 million patient visits annually and conduct over 100 million laboratory tests through leading edge technologies and our 6,000 talented and dedicated employees. We are a committed innovator in supporting Canadians to live healthier lives, operating Canada's first commercial genetics lab and the country's largest online patient portal, with more than 2.3 million Canadians receiving their results online. LifeLabs is 100% Canadian owned by OMERS Infrastructure, the infrastructure investment manager of one of Canada’s largest defined benefit pension plans. Learn more at www.lifelabs.com.
Ontario's doctors pleased with vaccination progress, optimistic about summer
TORONTO, June 30, 2021 /CNW/ - Ontarians have much to look forward to and be optimistic about this summer.
All the work the Ontario public, essential workers and front-line health-care workers have done during the pandemic, by following public health guidelines and getting themselves vaccinated, is finally starting to pay off. This is why it's more important than ever to continue following the remaining pandemic restrictions.
Ontario's doctors appreciate the sacrifices this has meant for everyone and the devastating losses to many families. But as we approach the first long weekend of summer, more than 75 per cent of adults in Ontario have received one COVID-19 shot and 34 per cent have had two. The number of people being infected by the virus, hospitalized and dying are all dropping.
"Ontario's continuing trend of increasing vaccinations and decreasing hospitalizations should give us hope and optimism for the future," said OMA President Dr. Adam Kassam. "While we race toward a crucial two-dose summer, we are thrilled that Ontarians will be able to spend time with friends and family and reconnect with their loved ones."
The OMA encourages anyone who has not received their first vaccination or who requires a second to do so as soon as possible. This is especially important for youths ages 12-17 whose vaccination rates have been lower than expected. Parents or anyone with questions about vaccines should talk to their family doctor, pediatrician or public health unit, who all have a critical role to play in explaining the benefits of vaccines and administering them.
The possible spread of the highly infectious and more severe Delta variant of the virus remains a concern, although the risks drop as more people are vaccinated. Vaccinations are the way out of the pandemic.
To ensure the third wave of the pandemic is the last significant wave, the OMA urges everyone to continue to follow public health guidelines such as those released by the Public Health Agency of Canada spelling out what is safe behaviour for people who are fully vaccinated compared with those who are partly or not vaccinated.
Doctors also urge everyone to be familiar with what exactly is permitted when the province moves to Step 2 of its reopening strategy on Wednesday. The OMA is encouraged to see the province continues to move cautiously in its reopening plan and is following the scientific evidence.
"Now is not the time to let down our guards when we have come so far to respond to this pandemic as a community," said OMA CEO Allan O'Dette. "By continuing to follow public health measures and getting vaccinated, you will allow the health-care system to respond to the significant number of patients needing critical services that have been delayed for so long."
It's time to change Ontario's health care for the better as the post-pandemic recovery begins. Complete our survey at betterhealthcare.ca and help shape the future of health care.
About the OMA
The Ontario Medical Association represents Ontario's 43,000 plus physicians, medical students and retired physicians, advocating for and supporting doctors while strengthening the leadership role of doctors in caring for patients. Our vision is to be the trusted voice in transforming Ontario's health-care system.
SOURCE Ontario Medical Association
Rritual Superfoods Featured in Syndicated Broadcast Covering Launch of Product Line in CVS Stores
VANCOUVER, British Columbia, June 30, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Rritual Superfoods Inc. ("Rritual" or the "Company") (CSE: RSF) (FSE: 0RW) (OTC: RRSFF), a fast-growing functional superfood company that creates natural wellness products which support a holistic approach to a healthy lifestyle, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers Rritual’s recent announcement that its premium brand of functional superfoods will launch in CVS stores across the USA.
"This phase one placement at CVS, the largest drugstore chain in the USA,1 is a significant milestone for Rritual's national retail rollout. In terms of the Rritual brand, placement with CVS further establishes confidence in our products and escalating demand for this category with consumers," stated Mr. David Kerbel, Rritual Superfoods CEO. "Rritual's placement in CVS is doubly significant because our products have been chosen for CVS's new HealthHUB locations, which aims to transform the 'consumer health experience' with education and personalized service from CVS trained professionals at the community level."
In 2020, CVS opened 650 HealthHUB locations, and it plans to have 1,500 locations open by the end of 2021. CVS HealthHUB locations offer online streams of wellness and nutrition content from its community rooms in place of in-person classes, and care concierges pivoted to focus on reaching out to patients telephonically.
Rritual is a fast-growing functional superfood company that creates natural wellness products which support a holistic approach to a healthy lifestyle. The company is poised to dominate a segment where demand and sales are growing exponentially. Under the executive leadership with over 100 years of CPG pedigree, Rritual has launched distribution to major retailers and is positioning itself to lead and define functional health and wellness industry as a superfood platform. Rritual markets organic wellness products in the United States through initial retail rollout which includes over 10,000 points of sale and through www.rritual.com.
NetworkNewsAudio (“NNA”), one of 50+ brands within the InvestorBrandNetwork (“IBN”), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Forward-Looking Information
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Rritual's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the Company's plans to leverage third party manufacturing and logistics, the Company's broader retail distribution plans and the Company's other plans, focus and objectives.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Rritual's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under "Forward-Looking Statements" and "Risk Factors" in the final long form prospectus of the Company dated February 26, 2021 and available under the Company's profile on SEDAR at www.sedar.com. Rritual undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Rritual to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Lucky Iron Fish receives $250k in funding to help address iron deficiency anemia in Benin.
Fund for Innovation and Transformation (FIT), a program designed to support Canadian small and medium-sized organizations (SMOs), has chosen Lucky Iron Fish as one of the SMOs to be funded for testing innovative solutions that advance gender equality. The $250k funding will help improve nutritional outcomes for women and children in Benin.
Toronto, June 30, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) is an impact-driven company that is on a mission to tackle iron deficiency globally using their innovative solutions designed to make iron intake more accessible to more people. In addition to selling directly to consumers, LIFe also partners with institutions, charitable organizations, and even community-based programs to work directly with undernourished families around the world.
For this project, LIFe will be working with their long-term partners at CARE Benin. With the help of the $250,000 funding, they will provide nutrition workshops and introduce the Lucky Iron Fish as a recommended addition to daily cooking in order to reduce prevalence of iron deficiency anemia. Since training can no longer be conducted in large group settings or by frontline workers at household level because of COVID-19, LIFe will be testing new digital tools and other innovations like “talking books” to provide information and influence behaviours to improve community health. This project aims to reduce women’s vulnerabilities due to the pandemic and also increase women’s decision-making roles in improving household nutrition.
Iron deficiency is a global health issue that impacts 1 out of 3 individuals (2+ billion worldwide), with women, girls, and children impacted at a disproportionately higher rate. It is a prevalent form of undernutrition that is directly linked to stunted cognitive development in children under 5; and in adults, it reduces work productivity, cognitive function, and can lead to poor pregnancy outcomes.
In fact, according to the World Bank, the economic costs of undernutrition, in terms of lost national productivity and lost economic growth, is 2%-3% of GDP in some countries and is as high as 11% of GDP in Africa and Asia each year.
In Benin alone, 62% of children under 5 and 47% of females of reproductive age suffer from iron deficiency anemia. Benin also ranks 26th in the world for its high maternal mortality which is commonly caused due to lack of access to health services and nutrition, among other things.
Addressing iron deficiency in undernourished communities goes hand in hand with addressing many of the sustainable development goals like gender equality, zero hunger, good health & well-being, reduced inequalities, and decent work & economic growth.
Switch Health reaches 1 Million COVID-19 tests in Canada's fight against COVID-19
TORONTO, June 30, 2021 /CNW/ - Switch Health today announced that it has conducted over one million COVID-19 tests in Canada since the beginning of the pandemic with its innovative at-home and mobile COVID-testing solutions.
Through its partnership with provincial and federal governments and some of Canada's top laboratories, Switch Health has provided testing with trusted healthcare professionals in Canadian homes, workplaces, airports, and multiple points of entry into the country throughout the pandemic. It has delivered reliable and accessible healthcare solutions across Canada, including remote areas, and provided dependable digital results to keep Canadians and their families safe.
"We are incredibly proud of this million-test milestone and the role we played in keeping Canadians safe during the pandemic," said Marc Thomson, Chief Operating Officer at Switch Health.
"We are a proudly Canadian company, driving Canadian-based innovation and technology, that has not only created over 2000 jobs during one of the most trying times in global history but also empowering Canadians to take more control of their health."
"We are transforming how Canada delivers healthcare through our patient-focused telehealth solutions that serve Canadians at their convenience," said Mary Langley, Chief Strategy Officer. "We look forward to bringing new services to Canadians to help address their healthcare needs for years to come."
Switch Health recently introduced AuraPass, a groundbreaking digital vaccine, and COVID-19 test result verification technology, as the next reliable solution in keeping Canadians safe, as the country begins to reopen for business. AuraPass will empower Canadians to share vaccination and testing status with partnering organizations to get back to favorite activities, whether that is attending a concert or hockey game, going to the movies, boarding a flight, or dining out at a restaurant.
About Switch Health
Switch Health Holdings Inc. (Switch Health) is an industry leader that is transforming how healthcare is delivered in Canada through cutting-edge decentralized next-generation diagnostics and patient-focused digital solutions. Switch Health developed an end-to-end, innovative, and accessible testing solution in Canada's fight against COVID-19, with its at-home and mobile collection kit to test Canadians safely, rapidly, and reliably for COVID-19. Switch Health offers its gold standard of rapid and PCR testing in over 200 languages from the comfort of peoples' homes or workplaces, with the guidance of trusted healthcare professionals and the delivery of results through some of Canada's top laboratories.
SOURCE Switch Health Inc.
Canada As One Inc. Announces Two-Million-Mask Donation to Frontline Workers
CALGARY, Alberta, June 29, 2021 (GLOBE NEWSWIRE) -- Canada As One Inc., a national mask distributor aligned with Breathe Medical Manufacturing, is donating two million medical and non-medical masks to frontline workers in Canada as a show of appreciation for their work throughout the pandemic. Frontline workers can individually access the free donation of masks on the Canada As One website. Access to the donation will remain open through August, or until supplies are fully distributed.
Canada As One is a mask distributor based in Calgary that works with Breathe Medical Manufacturing, a Kelowna-headquartered major mask manufacturer, to provide premium medical masks such as N95s and ASTM levels 1, 2 and 3 to healthcare and other organizations. Both companies were built on the premise that Canadians deserve timely access to quality protective masks. Their partnership arose as a response to the mask shortage that occurred at the beginning of the pandemic, during which time the Canadian government scrambled to import masks to supply frontline workers with the protection they urgently needed.
“It hurts knowing that our frontline workers once had to ration medical masks as they risked their lives each day. As a Canadian company, we feel a sense of responsibility to give back to those who have given so much to the public during the pandemic,” said David Lee, CEO of Canada As One. “The goal of Canada As One has always been to protect people with made-in-Canada masks, but we can continue to do so only if our governments choose to support Canadian mask manufacturing. We will be working tirelessly to conduct this rollout as smooth as possible. This mask giveaway is our sincere thank you to the millions of Canadian frontline workers for their continuing efforts on behalf of all Canadians.”
Over the next few months, the Canada As One team will be managing the mask giveaway program while also continuing to supply medical masks to critical healthcare and infrastructure organization and private business customers throughout Canada and around the world.
Frontline workers interested in receiving a no-charge giveaway of medical-grade masks from Canada As One can visit https://canadaasone.com/pages/thankyou.
About Canada As One Canada As One Inc. is a mask distributor licensed by Health Canada for national sales and distribution. The company was established in April 2020 in response to the COVID-19 pandemic. Canada As One has an exclusive relationship with Breathe Medical Manufacturing, one of the country’s largest mask producers. Together, they provide Canadians and the international community with masks that meet all national and international certifications and are manufactured using premium raw materials. Canadaasone.com.
4 Health Conditions You Can Help By Getting in Shape
If you want to take better control of your health, exercising more can point you in the right direction. By getting in better shape, you may even reverse certain medical conditions that you may have or at least alleviate some of their unpleasant symptoms. Exercise to lose body weight and achieve greater muscle development has been shown to help reduce the effects of these four medical conditions.
Arthritis
Extra weight on the body can put additional strain on the bones and joints, and this can be especially problematic if you have arthritis. By getting in better shape, you’ll reduce pressure on arthritic areas where pain may be felt more because of the excess fat surrounding them. Improving your fitness can also help strengthen areas around arthritic joints to give them better support so that they don’t ache as much.
Diabetes
Being overweight is one of the main causes of type 2 diabetes, and losing weight through diet and exercise may be enough to cure your diabetes altogether. Shedding the extra pounds can help lower your blood sugar levels and combat insulin resistance. If you’ve been diagnosed as prediabetic, starting afitness plan and working out as often as possible may be enough to prevent a full onset of diabetes.
Obstructive Sleep Apnea
Obstructive sleep apnea is a condition that often disrupts breathing patterns while sleeping. If you have this condition, you may find yourself waking up frequently while gasping for air. The reason why you’re having trouble breathing while sleeping when you have obstructive sleep apnea is because your breathing passage gets blocked from your throat muscles relaxing too much. The condition is often worsened from being overweight, and losing even a few pounds can make a big difference. If you’ve improved your fitness but still struggle with obstructive sleep apnea, using one of the available CPAP machines can help prevent disruptions to your breathing.
High Blood Pressure
Also known as hypertension, high blood pressure occurs when too much force is exerted on the walls of blood vessels as blood flows through them. Being out of shape coupled with a high-fat, high-sodium diet can make your high blood pressure worse and may even be the exact cause of the problem. Losing weight and developing better muscle tone may be enough to reverse your hypertension and lower your chances of having a heart attack or stroke. Exercise can also help strengthen the heart so that it won’t have to work as hard to pump blood throughout your body, and this can lower your blood pressure significantly.
Changing your physical fitness for the better may hold the key to stopping the damaging effects of certain medical conditions. By working with your doctor to develop the best exercise plan possible, you may improve your health for the long term.
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products, is pleased to announce it has initiated corporate support as one of TheraPsil’s first Core Spore Supporters through a generous donation and ongoing advocacy to the TheraPsil Coalition (“TheraPsil”) in support of their continued national initiatives aimed at increasing patient access to psilocybin.
Based in Victoria, British Columbia and established in 2019, TheraPsil is a non-profit coalition of healthcare professionals, patients, and advocates dedicated to obtaining legal access to psilocybin-assisted psychotherapy for Canadians in medical need. TheraPsil has facilitated precedent-setting and tangible progress in the fight for compassionate access to psilocybin therapy in Canada. It has helped Canadians suffering from end-of-life distress through advocacy efforts resulting in 'section 56 exemptions' granted directly from the Minister of Health, Patty Hadju, beginning on August 4th, 2020. These first exemptions represent a milestone event as the first instance of psilocybin being approved for patients since 1974 when it was made a controlled substance in Canada. TheraPsil has now successfully supported 31 patients in five Canadian provinces to gain access to legal, psilocybin-assisted psychotherapy.
Psilocybin-assisted psychotherapy is the professionally guided use of psilocybin in combination with psychotherapy. According to TheraPsil, research and anecdotal evidence has shown that psilocybin therapy can improve the quality of life and end-of-life care for individuals experiencing anxiety, depression, and hopelessness as a result of a life-threatening diagnosis.
The primary services of TheraPsil are patient-rights advocacy, assessment, and referral - connecting patients with exemptions with therapists trained in psilocybin assisted therapy. To this end, TheraPsil recognizes the importance of developing a pool of suitably trained and trusted clinical associates for referral purposes, and subsequently has created a training curriculum as the required context in which trainees may legally use psilocybin as part of their professional training. After 100 days of advocacy, on December 1st, 19 Healthcare Practitioners were granted their section 56 exemptions by Health Canada to legally consume psilocybin in the course of training. On March 1st, 2021 TheraPsil launched the beta-version of their training program, and to date, four training cohorts across the country have been launched with five more set to launch in the next three months.
Spencer Hawkswell, CEO of TheraPsil notes, “Natural psilocybin has been used for thousands of years, and now the science and medicinal benefits of psilocybin-assisted therapy are being proven not just on the clinical side, but in real settings with patients, delivering real life-changing results. Greater access to psilocybin therapy to reduce Canadian’s suffering is needed, and we are grateful for Optimi’s support of our on-going initiatives to facilitate compassionate access to patients in medical need across the nation, alongside professional training, public education and research.”
TheraPsil is a non-profit, Canadian organization that relies on donations to continuously advocate for Canadians in medical need. Every dollar donated will help TheraPsil advocate for psilocybin regulations in Canada through public education, research, and patient advocacy. Individuals interested in supporting the legalization of psilocybin therapy in Canada can support their current online fundraiser by clicking here.Corporate donors who are interested in becoming one of TheraPsil’s Core Spore Supporters are encouraged to reach out to TheraPsil’s Development Officer, Robyn Broekhuizen at Robyn@therapsil.ca.
Optimi Health’s Chairman JJ Wilson states, “Compassionate care for patients seeking relief from end-of-life situations is an ever-growing need. Patients living with on-going anxiety, depression, and related traumas deserve timely access to both the medicine and the therapeutic support. The philosophy behind TheraPsil is certainly in line with our views of all-natural human optimization as we aim to bring consistent dosing to natural psilocybin upon receipt of our dealer’s license. We are proud to support their upcoming efforts and hope the growing number of Optimi followers will take a moment to support their cause by visiting the TheraPsil website to consider how you too might help the efforts of this excellent organization.”
On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
FORWARD‐LOOKING STATEMENTS This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, "forward‐looking statements") that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements" and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Optimi Health Supports Patient-Focused Psilocybin Advocacy by TheraPsil
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products, is pleased to announce it has initiated corporate support as one of TheraPsil’s first Core Spore Supporters through a generous donation and ongoing advocacy to the TheraPsil Coalition (“TheraPsil”) in support of their continued national initiatives aimed at increasing patient access to psilocybin.
Based in Victoria, British Columbia and established in 2019, TheraPsil is a non-profit coalition of healthcare professionals, patients, and advocates dedicated to obtaining legal access to psilocybin-assisted psychotherapy for Canadians in medical need. TheraPsil has facilitated precedent-setting and tangible progress in the fight for compassionate access to psilocybin therapy in Canada. It has helped Canadians suffering from end-of-life distress through advocacy efforts resulting in 'section 56 exemptions' granted directly from the Minister of Health, Patty Hadju, beginning on August 4th, 2020. These first exemptions represent a milestone event as the first instance of psilocybin being approved for patients since 1974 when it was made a controlled substance in Canada. TheraPsil has now successfully supported 31 patients in five Canadian provinces to gain access to legal, psilocybin-assisted psychotherapy.
Psilocybin-assisted psychotherapy is the professionally guided use of psilocybin in combination with psychotherapy. According to TheraPsil, research and anecdotal evidence has shown that psilocybin therapy can improve the quality of life and end-of-life care for individuals experiencing anxiety, depression, and hopelessness as a result of a life-threatening diagnosis.
The primary services of TheraPsil are patient-rights advocacy, assessment, and referral - connecting patients with exemptions with therapists trained in psilocybin assisted therapy. To this end, TheraPsil recognizes the importance of developing a pool of suitably trained and trusted clinical associates for referral purposes, and subsequently has created a training curriculum as the required context in which trainees may legally use psilocybin as part of their professional training. After 100 days of advocacy, on December 1st, 19 Healthcare Practitioners were granted their section 56 exemptions by Health Canada to legally consume psilocybin in the course of training. On March 1st, 2021 TheraPsil launched the beta-version of their training program, and to date, four training cohorts across the country have been launched with five more set to launch in the next three months.
Spencer Hawkswell, CEO of TheraPsil notes, “Natural psilocybin has been used for thousands of years, and now the science and medicinal benefits of psilocybin-assisted therapy are being proven not just on the clinical side, but in real settings with patients, delivering real life-changing results. Greater access to psilocybin therapy to reduce Canadian’s suffering is needed, and we are grateful for Optimi’s support of our on-going initiatives to facilitate compassionate access to patients in medical need across the nation, alongside professional training, public education and research.”
TheraPsil is a non-profit, Canadian organization that relies on donations to continuously advocate for Canadians in medical need. Every dollar donated will help TheraPsil advocate for psilocybin regulations in Canada through public education, research, and patient advocacy. Individuals interested in supporting the legalization of psilocybin therapy in Canada can support their current online fundraiser by clicking here.Corporate donors who are interested in becoming one of TheraPsil’s Core Spore Supporters are encouraged to reach out to TheraPsil’s Development Officer, Robyn Broekhuizen at Robyn@therapsil.ca.
Optimi Health’s Chairman JJ Wilson states, “Compassionate care for patients seeking relief from end-of-life situations is an ever-growing need. Patients living with on-going anxiety, depression, and related traumas deserve timely access to both the medicine and the therapeutic support. The philosophy behind TheraPsil is certainly in line with our views of all-natural human optimization as we aim to bring consistent dosing to natural psilocybin upon receipt of our dealer’s license. We are proud to support their upcoming efforts and hope the growing number of Optimi followers will take a moment to support their cause by visiting the TheraPsil website to consider how you too might help the efforts of this excellent organization.”
On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
FORWARD‐LOOKING STATEMENTS This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, "forward‐looking statements") that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements" and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
